Importantly, the prognostic value of stromal Cav-1 loss in breast cancers has now been independently validated [98–101] and has been extended to multiple types of human cancers, such as colorectal cancer [44], advanced prostate cancer [102], metastatic melanoma [41], gastric cancer [103], and osteosarcoma [104]. This evidence concerns the gene CAV1 and gastric cancer.